Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director · Acting Chief Executive Officer | March 03, 2022 | March 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
vTv Therapeutics Inc.
Report date March 03, 2022 · Filed March 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2032-03-03 | Direct | 500,000 |
Reported balance
After 2022-03-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-03 · Grant · Acquired 500,000 · Balance 500,000 F1: 125,000 of the options vested on the date of grant and the remaining 375,000 options vest quarterly at rate of 31,250 every three months over three years beginning from March 1, 2022 subject to continued services as an employee or director. |
Filing footnotes · ownership attribution and instrument terms
F1: 125,000 of the options vested on the date of grant and the remaining 375,000 options vest quarterly at rate of 31,250 every three months over three years beginning from March 1, 2022 subject to continued services as an employee or director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2022 Filed Mar 5, 2022 01:51 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000950142-22-000901 · es220231439_4-nelson.xml · derivative · entry 1 Nelson Rich S. · CIK 0001833145 · Director · Acting Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A common stock · 500,000 shares Expires 2032-03-03 F1 · derivative.exercise_date: 125,000 of the options vested on the date of grant and the remaining 375,000 options vest quarterly at rate of 31,250 every three months over three years beginning from March 1, 2022 subject to continued services as an employee or director. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:03 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 10,000 | $2.86 | $28,600.00 |
DisclosureSEC source: 0001562180-21-001764 · primarydocument.xml · nonDerivative · entry 2 Nelson Rich S. · CIK 0001833145 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse as UTMA custodian for son. Disclosed balance after: 10,000 F1 · ownership.nature: Shares are held of record by the Reporting Person's spouse as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:03 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 50,000 | $2.86 | $143,000.00 |
DisclosureSEC source: 0001562180-21-001764 · primarydocument.xml · nonDerivative · entry 1 Nelson Rich S. · CIK 0001833145 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.